Analysts Set Expectations for VNDA FY2025 Earnings

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Equities research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Vanda Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the biopharmaceutical company will post earnings of $1.30 per share for the year. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($0.32) per share.

A number of other analysts have also weighed in on VNDA. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Vanda Pharmaceuticals in a research note on Tuesday. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Monday. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Trading Down 3.5 %

Shares of NASDAQ:VNDA opened at $4.35 on Thursday. Vanda Pharmaceuticals has a 12 month low of $3.46 and a 12 month high of $6.75. The firm’s 50-day moving average is $4.79 and its 200 day moving average is $5.02.

Insider Activity

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 5,000 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $5.17, for a total value of $25,850.00. Following the transaction, the director now owns 44,857 shares in the company, valued at $231,910.69. The trade was a 10.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 8.90% of the company’s stock.

Institutional Trading of Vanda Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its holdings in shares of Vanda Pharmaceuticals by 17.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,013,807 shares of the biopharmaceutical company’s stock valued at $11,379,000 after purchasing an additional 292,172 shares during the last quarter. Nantahala Capital Management LLC raised its stake in Vanda Pharmaceuticals by 57.3% in the second quarter. Nantahala Capital Management LLC now owns 1,593,516 shares of the biopharmaceutical company’s stock valued at $9,003,000 after buying an additional 580,265 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Vanda Pharmaceuticals by 7.1% in the third quarter. Geode Capital Management LLC now owns 1,425,827 shares of the biopharmaceutical company’s stock worth $6,689,000 after acquiring an additional 94,870 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Vanda Pharmaceuticals by 7.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 780,933 shares of the biopharmaceutical company’s stock valued at $3,663,000 after purchasing an additional 55,567 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Vanda Pharmaceuticals by 0.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 596,210 shares of the biopharmaceutical company’s stock worth $2,796,000 after purchasing an additional 3,473 shares in the last quarter. 88.14% of the stock is currently owned by institutional investors.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.